Saracatinib is primarily used in research and clinical studies as a potent inhibitor of Src family kinases, which are involved in various cellular processes including cell proliferation, differentiation, and survival. It has been investigated for its potential therapeutic effects in cancer treatment, particularly in cases where Src kinase activity is dysregulated, such as in certain types of breast, lung, and colorectal cancers. Additionally, saracatinib has been explored for its role in reducing inflammation and fibrosis, making it a candidate for treating conditions like idiopathic pulmonary fibrosis. Its ability to cross the blood-brain barrier has also led to studies examining its efficacy in neurodegenerative diseases, including Alzheimer's disease, where it may help modulate synaptic function and reduce amyloid-beta-related pathology.